Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RF07002 for Maintenance Treatment of Opioid Dependence
CTR20130579Phase 2Completed
- Sponsor
- Yichang Humanwell Pharmaceutical Co., Ltd.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in opioid use disorder (OUD) comparing RF07002 with Placebo (RF07002 mimetic) (2 arms). Primary endpoints: Adverse events and adverse drug reactions and Visit retention rate comparison between the two groups over the maintenance period. Started Oct 2019; status: completed.
02
Drugs
SK1808
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on CTR20130579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130579.